Stonepine Capital Management LLC boosted its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 19.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 739,917 shares of the specialty pharmaceutical company’s stock after buying an additional 120,379 shares during the period. Cumberland Pharmaceuticals accounts for 2.9% of Stonepine Capital Management LLC’s portfolio, making the stock its 14th largest position. Stonepine Capital Management LLC owned about 4.62% of Cumberland Pharmaceuticals worth $5,135,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of CPIX. Morgan Stanley increased its position in Cumberland Pharmaceuticals by 15.2% in the first quarter. Morgan Stanley now owns 21,615 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 2,844 shares during the last quarter. Ameriprise Financial Inc. bought a new position in Cumberland Pharmaceuticals during the first quarter valued at about $165,000. Geode Capital Management LLC increased its position in Cumberland Pharmaceuticals by 7.4% in the first quarter. Geode Capital Management LLC now owns 52,092 shares of the specialty pharmaceutical company’s stock valued at $361,000 after buying an additional 3,576 shares during the last quarter. Acadian Asset Management LLC increased its position in Cumberland Pharmaceuticals by 3.4% in the first quarter. Acadian Asset Management LLC now owns 130,430 shares of the specialty pharmaceutical company’s stock valued at $905,000 after buying an additional 4,257 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Cumberland Pharmaceuticals by 4.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,000 shares of the specialty pharmaceutical company’s stock valued at $1,414,000 after buying an additional 9,900 shares during the last quarter. Institutional investors own 34.48% of the company’s stock.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) traded up 0.29% on Tuesday, hitting $6.92. 2,604 shares of the stock traded hands. Cumberland Pharmaceuticals Inc. has a 52 week low of $4.40 and a 52 week high of $7.48. The firm’s 50 day moving average is $6.64 and its 200 day moving average is $6.16. The stock’s market cap is $110.95 million.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Monday, May 15th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter. The firm had revenue of $9.64 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 5.63% and a positive return on equity of 1.93%. Equities analysts anticipate that Cumberland Pharmaceuticals Inc. will post $0.09 earnings per share for the current year.
In other Cumberland Pharmaceuticals news, Director Thomas R. Lawrence sold 6,000 shares of the company’s stock in a transaction dated Friday, April 7th. The shares were sold at an average price of $6.40, for a total value of $38,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 38.00% of the company’s stock.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.
Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.